Broncholab™ is a platform where CT-scan data of individual persons can be uploaded and analyzed with FRI-technology. The results of this analysis is then sent to the attending physician alone, observing all privacy requirements. Broncholab provides physicians with reproducible CT values for pulmonary tissue for providing quantitative support for diagnosis and follow-up examination. Broncholab can be used to sup-port physicians in the diagnosis and documentation of pulmonary tissues images (e.g., abnormalities) from CT thoracic datasets. 3D segmentation and isolation of sub compartments, volumetric analysis, density evaluations, low density cluster analysis, fissure evaluation and reporting tools are combined with a dedicated workflow.
All information of the lungs is collected on regional level, increasing insights in the nature of the disease and helping to understand what happens locally. Enables accurate monitoring of the course of the disease, in this way facilitating early adjustments to therapy.
Provides detailed quantitative representations of CT images, supporting physicians in diagnosis and follow-up. Broncholab blood vessel density sub-compartments (BV5, BV5_10, etc.) can be used to detect changes in lung structure which may be associated with pulmonary vascular remodelling and other pathologic processes involved in the development of chronic respiratory and pulmonary vascular disease.
Healthy areas in the lung tend to compensate for sick areas, therefor severity of respiratory diseases is often underestimated by conventional lung function tests like spirometry, which can indicate normal lung function despite declining lung health.
Quantitative HRCT techniques such as FRI yields more accurate regional information that is clinically relevant for early and correct diagnosis and to optimize treatments for individual patients.
The FDA provided market clearance to Fluidda for its Broncholab platform in March 2020. Broncholab provides several Functional Respiratory Imaging (FRI) parameters to physicians via an online platform to assist in diagnosing and monitoring of respiratory diseases.
Dr. Jan De Backer, Fluidda’s CEO, states. “Broncholab now extends these capabilities into clinical practice which is a tremendous step forward in our quest for better respiratory care. We are living in a time where respiratory viruses cause significant disruption to daily life with high associated cost. We are striving to better understand respiratory illnesses with our novel technology to be more prepared for the next viral outbreak and to deal with the increased number of patients with lung diseases worldwide.”
This authorization is valid for so long as the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 is in effect.